DEFA14A: Seres Therapeutics Highlights Pipeline Progress and Vowst Transaction at Canaccord Genuity Growth Conference

Seres Therapeutics discussed the sale of Vowst to Nestl, the upcoming SER-155 data readout, and the potential of its microbiome therapeutics platform at the Canaccord Genuity Growth Conference.

Summary

• Seres Therapeutics is focused on developing novel bacterial therapies for life-threatening infections in medically vulnerable patients.
• The company's first successfully developed therapeutic, Vowst, was approved in April 2023 for recurrent C.difficile infection.
• Seres announced the sale of Vowst to Nestl Health Science for $175 million upfront, plus a prepaid sales-based milestone and an equity investment.
• The transaction is expected to close within 90 days of the August 6th deal signing.
• Seres is developing SER-155, currently in a Phase 1b study for cancer patients who have received allo stem cell transplants, with data expected in September.
• SER-147, a second bacterial composition, is being developed for chronic liver disease and is expected to enter the clinic next year.
• The company believes its approach of using healthy human-derived bacteria provides important safety dimensions.
• Positive results from the SER-155 Phase 1b study could lead to an accelerated path to approval, potentially resembling the Vowst experience.
• Seres is also exploring opportunities for further development in autologous stem cell transplants and AML.
• The company has established capabilities to identify disease targets, optimize candidates, and move to clinical studies quickly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The sale of Vowst provides financial stability, and the pipeline progress is encouraging. However, the company's history of losses and need for additional funding temper the overall outlook.

Positives

• Vowst is a successfully developed therapeutic that has transformed thousands of patients' lives.
• The sale of Vowst to Nestl provides Seres with a meaningful short-term infusion of capital to continue development of its therapeutic pipeline.
• SER-155 has shown encouraging results in the first cohort of the Phase 1b study.
• The company's approach of using healthy human-derived bacteria provides important safety dimensions.
• Seres has received fast-track designation from the FDA for SER-155.
• The company has established capabilities to identify disease targets, optimize candidates, and move to clinical studies quickly.

Negatives

• The company has incurred significant losses and is not currently profitable.
• The company needs additional funding.
• The company has a history of operating losses.
• The company relies on third parties to conduct its clinical trials and manufacture its product candidates.

Risks

• The company faces competition in the development of microbiome therapeutics.
• The company's ability to protect its intellectual property is crucial.
• The company's ability to retain key personnel and manage its growth is important.
• The transaction with Nestl could be terminated.
• The company may fail to obtain stockholder approval for the proposed transaction.
• The company may not receive the installment payments or the milestone payments in the future.
• The company may not be able to realize the anticipated benefits of the proposed transaction.

Future Outlook

Seres expects the transaction with Nestl to close within 90 days and is focused on advancing its pipeline, starting with the SER-155 data readout in September. The company plans to engage regulators to confirm an accelerated path to approval for SER-155 if the Phase 1b study is positive and is exploring opportunities for further development in other indications.

Management Comments

• Eric Shaff: 'We live and embrace the idea of transforming patients' lives using consortia of bacteria as therapy.'
• Eric Shaff: 'Vowst is the best evidence that these therapeutics are not an aspiration or a hope to help patients in the future, they are transforming lives now.'
• Eric Shaff: 'We expect to emerge from this transaction with a clear line of sight to support SER-155 and what comes after it following our imminent SER-155 phase 1b readout expected in September.'

Industry Context

The presentation highlights the growing interest in microbiome-based therapies and the potential to address unmet needs in medically vulnerable patient populations. The success of Vowst and the development of SER-155 and SER-147 position Seres as a key player in this emerging field.

Comparison to Industry Standards

• The mention of Prevymis, a Merck product, achieving $600+ million in 2023 revenues sets a benchmark for the potential commercial opportunity in allo-HSCT patients.
• The company's approach of using healthy human-derived bacteria aligns with the industry trend of developing safer and more targeted therapies.
• The company's focus on medically vulnerable patient populations is consistent with the industry's efforts to address unmet needs in specific disease areas.

Stakeholder Impact

• Shareholders will benefit from the capital infusion from the Vowst sale and the potential for pipeline progress.
• Patients will benefit from the continued availability of Vowst and the potential development of new therapies for life-threatening infections.
• Employees will be impacted by the sale of Vowst and the company's strategic focus on pipeline development.

Next Steps

• The company expects the transaction with Nestl to close within 90 days.
• The company anticipates the SER-155 Phase 1b study data readout in September.
• The company plans to engage regulators to confirm an accelerated path to approval for SER-155 if the Phase 1b study is positive.
• The company is exploring opportunities for further development in autologous stem cell transplants and AML.
• SER-147 is expected to enter the clinic next year.

Key Dates

Keywords

SER-155, SER-147, Vowst, microbiome, Nestl, C.difficile, allo-HSCT, bacterial therapies, infections, clinical trials